American Diabetes Association.: Report of the Expert Comittee on the diagnosis and clasification of Diabetes Mellitus. Diabetes Care. 1997; 20: 1183-1197

American Diabetes Association. Standards of Medical Care for Patients with Diabetes Mellitus. Clinical Practice Recomendations. Diabetes Care 2000; 23 (supl.1):s32-42.

Canadian Diabetes Association: 1998 clinical guidelines for the management of diabetes in Canada. CMAJ. 1998; 159 (sup 8): s1-s29

DeFronzo RA. Pharmacologic Therapy for type 2 diabetes mellitus. Ann Inter Med 1999; 131:281-303

European Arterial Risk Policy Group. A Strategy for Arterial Risk Assessment and Manegement in Type 2 Diabetes Mellitus. Diabetic Med 1997;14:611-621

European Diabetes Policy Group. A Desktop Guide to Type 2 Diabetes Mellitus. Guidelines for Diabetes Care. Diabetic Med. 1999; 16: 716-30.

Grundy S, Ivor J, Gregory L et al. Diabetes and Cardiovascular Disease. A Statement for Healthcare Professionals From the American Heart Association. Circulation 1999; 100: 1134-46

Haffner S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction. N Engl J Med 1998; 339: 229-34

Metzger, BE; Custan, DR.: The Organizing Committee Summary and recommendations of the Fourth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 1998; vol 21 (suppl 2): B161-

Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356-360

Report of the Joint National Committe on Prevention, detecction , Evaluation and treatment of high blood pressure (JNV VI). Arc Int Med. 1997; 157:2413-2446.

Sociedades Españolas de Diabetes, Endocrinología, Medicina Familiar y Comunitaria y Nefrología. Documento de consenso sobre pautas de detección y tratamiento de la nefropatía diabética en España. Aten Primaria 1998; 21: 471-476

The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1933;329:977-986.

Turner RC, Cull CA, Frighi V, Holman RR for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 Diabetes Mellitus. Progressive requirement for Multiple Therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.

United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-852

United Kingdom Prospective Diabetes Study Group. Effect of Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-864.

United Kingdom Prospective Diabetes Study (UKPDS) Group. Tight blood presure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703- 13

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720

Wilson PW, D´Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories.Circulation 1998; 97: 1837-47

Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial Points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999; 22 (Suppl 2): B59-B64.